BI’s Article search uses Boolean search capabilities. If you are not familiar with these principles, here are some quick tips.

To search specifically for more than one word, put the search term in quotation marks. For example, “workers compensation”. This will limit your search to that combination of words.

To search for a combination of terms, use quotations and the & symbol. For example, “hurricane” & “loss”.

Login Register Subscribe

Pharmaceutical firm to pay $39M to settle U.S. kickback claims


(Reuters) — The U.S. subsidiary of global pharmaceutical company Daiichi Sankyo Co Ltd. has agreed to pay $39 million to the U.S. government and state Medicaid programs to settle claims it paid doctors kickbacks to prescribe its drugs, the Department of Justice said on Friday.

The deal comes out of a whistleblower lawsuit filed by former Daiichi sales representative Kathy Fragoules, who will get $6.1 million of the settlement.

The lawsuit claimed Daiichi Sankyo Inc. paid kickbacks to doctors in the form of speaking fees at programs it hosted from 2004 until 2011. The doctors were sometimes even paid for speaking only to their own staff over “lavish” dinners hosted by Daiichi, according to the DOJ.

Daiichi allegedly paid the kickbacks to get doctors to prescribe its high blood pressure drugs Azor, Benicar and Tribenzor, and its cholesterol-lowering drug Welchol.

In addition to the $39 million payment, Daiichi has agreed to make internal reforms, the DOJ said.

“We are pleased to have finalized these agreements and remain focused on our core mission of helping people live healthy and meaningful lives,” Ken Keller, president of Daiichi’s U.S. commercial operations, said in a statement.

The company, founded in Japan, has U.S. headquarters in New Jersey.

Read Next

  • Drug provider Omnicare settles suit over alleged kickbacks for $4.2M

    Long-term care pharmacy firm Omnicare Inc. has agreed to pay the government $4.2 million to settle charges in a whistle-blower suit that it engaged in a kickback scheme with a drug manufacturer in violation of the False Claims Act, the U.S. Department of Justice said Thursday.